SECTOR
Zydus Lifesciences gets USFDA’s final approval for Deflazacort oral suspension
Oct-06-2025

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) for Deflazacort oral suspension (USRLD: Emflaza Oral Suspension, 22.75 mg/mL).

Deflazacort oral suspension is indicated for treating Duchenne Muscular Dystrophy (DMD) in patients 5 years of age and older. Deflazacort belongs to a group of medications called steroids. It works by decreasing inflammation and slowing down an overactive immune system. Deflazacort oral suspension will be produced at Doppel, Italy.

The group now has 424 approvals and has so far filed 487 ANDAs since the commencement of the filing process in FY 2003-04. 

Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.


  RELATED NEWS >>